- Home
- TARA
as 11-15-2024 4:00pm EST
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 52.4M | IPO Year: | N/A |
| Target Price: | $24.00 | AVG Volume (30 days): | 235.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $5.24 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Protara Therapeutics Inc. (TARA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | TARA | 10% Owner | Sep 11 '24 | Sell | $1.71 | 158,901 | $271,715.44 | 45,000 | |
| Opaleye Management Inc. | TARA | 10% Owner | Sep 9 '24 | Sell | $1.83 | 61,992 | $114,250.89 | 45,000 |
Latest Protara Therapeutics Inc. News
TARA Breaking Stock News: Dive into TARA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
GlobeNewswire
5 days ago
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
11 days ago
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
GlobeNewswire
a month ago
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
GlobeNewswire
2 months ago
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
GlobeNewswire
2 months ago
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
GlobeNewswire
2 months ago
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Simply Wall St.
3 months ago
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
Compare TARA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TARA Protara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.